A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.

David W Borhani; David J Calderwood; Michael M Friedman; Gavin C Hirst; Biqin Li; Adelaine K W Leung; Brad McRae; Sheldon Ratnofsky; Kurt Ritter; Wendy Waegell

doi:10.1016/j.bmcl.2004.02.101

A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.

Identifier:nobleid.org/w1/20260515/0328FEC3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/0328FEC3.svg?ark=w1%2F20260515%2F0328FEC3)](https://nobleid.org/work/w1/20260515/0328FEC3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.

Identifier:nobleid.org/w1/20260515/0328FEC3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/0328FEC3.svg?ark=w1%2F20260515%2F0328FEC3)](https://nobleid.org/work/w1/20260515/0328FEC3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work